Eval. of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery

Inclusion Criteria: * Confirmed rectal cancer to the lower two-thirds of the rectum (higher and T2 N0 or N+) * Amenable for standard surgery procedures using electrocautery, argon beam, lasers or other conventional tissue removal modalities * ECOG status ≤ 2 * Life expectancy \>3 months * Age ≥ 18 years old * Age ≤ 80 years old * Ability to provide written informed consent and HIPAA forms prior to admission to this study * Willingness to meet all of the expected requirements of this clinical protocol Exclusion Criteria: * Patient with metastasis * History of radiotherapy or chemotherapy for the treatment of rectal cancer * Uremia - BUN\>40 * Hemodialysis * Existing urinary or fecal incontinence * Pregnant or lactating * Previously diagnosed coagulopathy or bleeding diathesis * Currently, or within the previous 10 days prior to surgery, taking any medications that would produce bleeding diathesis including but not limited to, Plavix, warfarin, NSAIDs, clopidogrel, ticlopidine or valproic acid * History of significant cardiac disorders that would necessitate special fluid management protocols * History of acute myocardial infarction and/or acute angina * INR \>1.4 in the 24 hours prior to surgery * PTT \>40 in the 24 hours prior to surgery * Platelet count \<100K in the 24 hours prior to surgery